HC Wainwright Reiterates Buy Rating for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on BioLineRx in a report on Thursday, October 31st. They set a “hold” rating on the stock.

BioLineRx Stock Performance

Shares of BioLineRx stock opened at $0.45 on Wednesday. BioLineRx has a 12-month low of $0.39 and a 12-month high of $1.93. The stock has a market cap of $36.08 million, a P/E ratio of -1.00 and a beta of 1.48. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. The business’s 50 day moving average is $0.53 and its 200-day moving average is $0.63.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. Equities research analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BLRX. CVI Holdings LLC acquired a new position in shares of BioLineRx during the 2nd quarter worth approximately $462,000. PVG Asset Management Corp acquired a new position in BioLineRx in the 2nd quarter valued at $70,000. Finally, Atria Investments Inc grew its holdings in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.